{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-046546","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-10-09T20:30:23+00:00","discovered_at":"2026-10-09T20:32:00.264541+00:00","generated_at":"2026-10-12T15:06:29.601230+00:00","sec_items":["1.01","2.01","9.01","3.02","5.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO","bullets":["Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.","The Purchase Agreement caps issuance at 19.99% of post-issuance outstanding shares, with any reduction settled in cash; shares have a six-month lock-up and piggyback registration rights.","At closing Hepion paid Canton $1,000,000 and GLS paid $125,000 toward the Canton Seller Note; Hepion became sole obligor/guarantor of remaining obligations.","Four Hepion directors, including Stetz and Appajosyula, are GLS officers/Sole Member shareholders and recused themselves; disinterested directors approved with a Ryan Valuation fairness opinion.","Effective Oct. 9, 2026, Sireesh Appajosyula became CEO and Gary Stetz became CFO; Appajosyula was Gravitas Life Sciences' former CEO and Stetz was Hepion's interim CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-046546","json":"https://secwatch.observer/filing/0001493152-26-046546.json","markdown":"https://secwatch.observer/filing/0001493152-26-046546.md","text":"https://secwatch.observer/filing/0001493152-26-046546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:06:29.601230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfdbe15c72","claim":"Sireesh Appajosyula was appointed as Chief Executive Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e1f7219d2b","claim":"Gary Stetz was appointed as Chief Financial Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}